TY - JOUR
T1 - Neuroblastoma survivors at risk for developing subsequent neoplasms
T2 - A systematic review
AU - Westerveld, Aimée S.R.
AU - van Dalen, Elvira C.
AU - Asogwa, Ogechukwu A.
AU - Koopman, Maria M.W.
AU - Papadakis, Vassilios
AU - Laureys, Geneviève
AU - van der Pal, Helena J.H.
AU - Kremer, Leontien C.M.
AU - Tytgat, Godelieve A.M.
AU - Teepen, Jop C.
N1 - Copyright © 2022 Elsevier Ltd. All rights reserved.
PY - 2022/3
Y1 - 2022/3
N2 - Neuroblastoma survivors have an increased risk of unfavorable long-term health outcomes, of which developing subsequent neoplasms is one of the most serious. We aimed to provide an overview of the current knowledge on the risk of subsequent neoplasms in neuroblastoma survivors. We conducted a systematic literature search in Medline/Pubmed (01–01-1945–13-01–2022) to identify studies that reported on ≥ 100 neuroblastoma survivors and assessed subsequent neoplasms as an outcome. We identified 410 potentially eligible articles, of which we eventually included 13 reports. All articles described retrospective cohorts with sizes varying from 145 to 5,987 neuroblastoma survivors. Within these cohorts 0.7% – 17.2% of the survivors developed a subsequent neoplasm. A wide variety of types of subsequent malignant and non-malignant neoplasms were observed, of which thyroid carcinoma and acute myeloid leukemia were most frequently reported. The risk of developing a subsequent neoplasm was 2.8 to 10.4 times higher in neuroblastoma survivors than in the general population. Although no statistically significant risk factors for subsequent neoplasms were observed in multivariable analyses, high-risk group survivors, women and those treated with radiotherapy seemed to have a higher risk. In conclusion, the studies in this systematic review consistently show that neuroblastoma survivors are at elevated risk of developing subsequent neoplasms. Future research should further explore risk factors for subsequent neoplasms in neuroblastoma survivors, so future treatment protocols and follow-up care can be improved.
AB - Neuroblastoma survivors have an increased risk of unfavorable long-term health outcomes, of which developing subsequent neoplasms is one of the most serious. We aimed to provide an overview of the current knowledge on the risk of subsequent neoplasms in neuroblastoma survivors. We conducted a systematic literature search in Medline/Pubmed (01–01-1945–13-01–2022) to identify studies that reported on ≥ 100 neuroblastoma survivors and assessed subsequent neoplasms as an outcome. We identified 410 potentially eligible articles, of which we eventually included 13 reports. All articles described retrospective cohorts with sizes varying from 145 to 5,987 neuroblastoma survivors. Within these cohorts 0.7% – 17.2% of the survivors developed a subsequent neoplasm. A wide variety of types of subsequent malignant and non-malignant neoplasms were observed, of which thyroid carcinoma and acute myeloid leukemia were most frequently reported. The risk of developing a subsequent neoplasm was 2.8 to 10.4 times higher in neuroblastoma survivors than in the general population. Although no statistically significant risk factors for subsequent neoplasms were observed in multivariable analyses, high-risk group survivors, women and those treated with radiotherapy seemed to have a higher risk. In conclusion, the studies in this systematic review consistently show that neuroblastoma survivors are at elevated risk of developing subsequent neoplasms. Future research should further explore risk factors for subsequent neoplasms in neuroblastoma survivors, so future treatment protocols and follow-up care can be improved.
KW - Child
KW - Late effects
KW - Neuroblastoma
KW - Subsequent neoplasms
KW - Survivors
KW - Systematic review
KW - Humans
KW - Risk Factors
KW - Forecasting
KW - Neoplasms
KW - Female
KW - Retrospective Studies
KW - Neoplasms, Second Primary/epidemiology
KW - Neuroblastoma/epidemiology
KW - Child
KW - Late effects
KW - Neuroblastoma
KW - Subsequent neoplasms
KW - Survivors
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85124397599&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/e3e8db06-2a53-3af9-8c49-55d15a3bb03a/
U2 - 10.1016/j.ctrv.2022.102355
DO - 10.1016/j.ctrv.2022.102355
M3 - Article
C2 - 35158111
AN - SCOPUS:85124397599
SN - 0305-7372
VL - 104
SP - 102355
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
M1 - 102355
ER -